36 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2037. from the record
Of the 19 now held by other companies, 19 name Atrium Therapeutics Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2037
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2038 · Medium confidence
Also notable
Ends Jan 2038 · Low confidence
Also notable
Ends Mar 2041 · High confidence
Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy
US 11,246,941
Cited by 68 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2038.
Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
US 10,994,020
The most cited patent in this portfolio, cited by 107 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Compositions and Methods of Treating Muscle Dystrophy
US 11,446,387
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2041.
Formerly held, still cited
Notable
Ends Dec 2039 · Medium confidence
Cited by 70 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
now held by Atrium Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Compositions and Methods of Treating Muscle Dystrophy (US 11,707,532) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy (US 11,712,478) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy (US 11,872,287) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy (US 11,912,779) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
What they patent
The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy | 10 in force | to Dec 2038 |
| Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping | 5 in force | to Feb 2038 |
| Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy (2022) | 4 in force | to Sep 2042 |
| Compositions and Methods of Treating Muscle Dystrophy | 4 in force | to Mar 2041 |
| Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy (2021) | 4 in force | to Mar 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,844,385 | Beta-Catenin Nucleic Acids and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,858,656 | Kras Nucleic Acids and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,876,121 | Egfr Nucleic Acids and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,994,020 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | In force | Low confidence | |
| US 11,179,472 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | In force | Low confidence | |
| US 11,311,627 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | In force | Low confidence | |
| US 11,400,163 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | In force | Low confidence | |
| US 12,064,483 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | In force | Low confidence | |
| US 10,881,743 | Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy In force · Medium confidence | In force | Medium confidence | |
| US 11,246,941 | Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 36: 19 patents in force now held by others · 31 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.